Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias

Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Christopher D., Bonkovsky, Herbert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465260/
https://www.ncbi.nlm.nih.gov/pubmed/36105850
http://dx.doi.org/10.1016/j.ymgmr.2022.100915
_version_ 1784787757028081664
author Ma, Christopher D.
Bonkovsky, Herbert L.
author_facet Ma, Christopher D.
Bonkovsky, Herbert L.
author_sort Ma, Christopher D.
collection PubMed
description Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that elagolix is porphyrogenic; thus, elagolix should be avoided or used with caution in patients with the AHPs.
format Online
Article
Text
id pubmed-9465260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94652602022-09-13 Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias Ma, Christopher D. Bonkovsky, Herbert L. Mol Genet Metab Rep Short Communication Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that elagolix is porphyrogenic; thus, elagolix should be avoided or used with caution in patients with the AHPs. Elsevier 2022-09-07 /pmc/articles/PMC9465260/ /pubmed/36105850 http://dx.doi.org/10.1016/j.ymgmr.2022.100915 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Ma, Christopher D.
Bonkovsky, Herbert L.
Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title_full Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title_fullStr Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title_full_unstemmed Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title_short Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
title_sort elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465260/
https://www.ncbi.nlm.nih.gov/pubmed/36105850
http://dx.doi.org/10.1016/j.ymgmr.2022.100915
work_keys_str_mv AT machristopherd elagolixisporphyrogenicandmayinduceporphyricattacksinpatientswiththeacutehepaticporphyrias
AT bonkovskyherbertl elagolixisporphyrogenicandmayinduceporphyricattacksinpatientswiththeacutehepaticporphyrias

Ejemplares similares